A Lyophilizable Nanoparticle Vaccine Specific for a Novel Linear Neutralizing Epitope in the α2-α3 Helices of Domain 3 of Lethal Factor from Bacillus anthracis
Toxins · 2025
DOI: 10.3390/toxins17080422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Jon Oscherwitz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105, USA. Hauptthemen laut MEDLINE: Antigens, Bacterial, Anthrax Vaccines, Bacterial Toxins, Bacillus anthracis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Anthrax remains a serious bioterrorism threat for which new and thermostable vaccines are needed. We previously demonstrated that immunization of rabbits with multiple-antigenic-peptide (MAP) vaccines elicit antibody (Ab) against the loop-neutralizing-determinant (LND), a cryptic linear neutralizing epitope in the 2β2-2β3 loop of protective antigen (PA) from Bacillus anthracis (B. anthracis), which mediates the complete protection of rabbits from inhalation spore challenge with B. anthracis Ames strain. Importantly, LND-specific Ab is not significantly elicited with PA-based vaccines. In the current study, we sought to identify a second unique neutralizing epitope which would also not overlap with the neutralizing specificities elicited by PA-based vaccines, and which could be combined with an LND vaccine as a prototype bivalent vaccine for anthrax. We evaluated linear peptide sequences in the α2-α3 helices of domain 3 of lethal factor (LF) in the form of virus-like particle (VLP) vaccines. Immunogenicity studies confirmed the presence of a 20-mer peptide sequence that is capable of eliciting protective levels of neutralizing Ab following two immunizations of rabbits using human-use adjuvants, and lyophilization of the VLPs did not diminish their immunogenicity. To our knowledge, this is the first demonstration that immunization with linear peptide sequences from LF can elicit protective levels of neutralizing Ab in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105, USA.
- Veterans Administration Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI 48105, USA.
- VLP Biotech, Inc., 3030 Bunker Hill St., Ste 117D, San Diego, CA 92109, USA.
- Department of Biostatistics, University of Michigan, Ann Arbor, MI 48105, USA.
ORCID-Profile: Thomas Braun, David Whitacre
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Oscherwitz, J., Cease, K., Milich, D., Braun, T., Yu, F., & Whitacre, D. (2025). A Lyophilizable Nanoparticle Vaccine Specific for a Novel Linear Neutralizing Epitope in the α2-α3 Helices of Domain 3 of Lethal Factor from Bacillus anthracis. Toxins. https://doi.org/10.3390/toxins17080422
Vancouver
Oscherwitz J, Cease K, Milich D, Braun T, Yu F, Whitacre D. A Lyophilizable Nanoparticle Vaccine Specific for a Novel Linear Neutralizing Epitope in the α2-α3 Helices of Domain 3 of Lethal Factor from Bacillus anthracis. Toxins. 2025. doi:10.3390/toxins17080422
BibTeX
@article{Oscherwitz2025,
author = {Oscherwitz, Jon and Cease, Kemp and Milich, David and Braun, Thomas and Yu, Fen and Whitacre, David},
title = {A Lyophilizable Nanoparticle Vaccine Specific for a Novel Linear Neutralizing Epitope in the α2-α3 Helices of Domain 3 of Lethal Factor from Bacillus anthracis},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17080422}
}
EUVIMED